DUALITYBIO-B(09606): The A-share prospectus has been published on the Shanghai Stock Exchange website for advance disclosure.
YingEn Biotechnology-B (09606) announces that, in accordance with relevant laws and regulations in China, the company's initial public offering of Renminbi ordinary shares (A shares) and the prospectus for listing on the Science and Technology Innovation Board (application draft) (A share prospectus) have been pre-disclosed on the website of the Shanghai Stock Exchange (http://www.sse.com.cn).
DUALITYBIO-B (09606) announcement, in accordance with the relevant laws and regulations of China, the company's initial public offering of Renminbi ordinary shares (A shares) and the prospectus for listing on the Science and Technology Innovation Board (A-share prospectus) have been disclosed on the website of the Shanghai Stock Exchange (http://www.sse.com.cn) for advance disclosure.
Related Articles
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?
New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.
How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
RECOMMEND
